ten23 health | AI Transformation Index

Overview

ten23 health is a Swiss CDMO (Contract Development and Manufacturing Organization) that earns fee-for-service revenue by developing, manufacturing, and analytically testing sterile injectable pharmaceutical products — primarily biologics — for biotech startups and established pharma companies.

Executive Summary

ten23 health is among the most durable CDMO assets a PE firm can own in an AI era: its core product — physically manufactured, regulatory-released sterile injectables — is categorically immune to AI substitution, and its GMP infrastructure, dual FDA/Swissmedic approvals, and client revalidation switching costs create layered structural protection that AI-native entrants cannot circumvent. The AI opportunity, however, is genuinely limited — this is a physical manufacturing business, not a cognitive labor business, and the incremental gains from AI-assisted formulation development and documentation are real but modest in the context of the total P&L. The strategic implication for 3i is that AI is not a material risk and not a material opportunity catalyst here; the investment thesis rests on CDMO market growth, capacity utilization, and the ongoing biotech outsourcing wave — not on AI transformation.

Durability Rationale

ten23 health's durability is rooted in an almost uniquely strong combination of physical irreplaceability and regulatory entrenchment: no AI model can aseptically fill a vial of injectable biologic, and no AI-native entrant can obtain FDA and Swissmedic GMP approval without years of capital investment and regulatory process. The business sits at the execution layer of the pharmaceutical supply chain — it IS the infrastructure, not a coordinator sitting above it — which eliminates disintermediation risk entirely. High client switching costs, driven by mandatory process revalidation and regulatory transfer requirements, further cement incumbent position, making this one of the most structurally durable business models in the healthcare services universe.

Opportunity Rationale

AI's transformative potential for ten23 health is structurally limited by the physical nature of the core production function: aseptic fill-finish and GMP manufacturing cannot be accelerated or replaced by cognitive AI, only supported at the margins. The genuine AI opportunity lies in formulation development and analytical workflows, where expert scientific judgment can be augmented to compress development timelines and reduce iteration cycles — but this represents a minority of total revenue and value creation. The business lacks the large-scale cognitive labor force (thousands of knowledge workers doing repeatable analytical tasks) that characterizes the highest-opportunity AI transformation targets; its 150-person workforce is dominated by physical operators, quality specialists, and scientists working on bespoke projects rather than high-volume, AI-compressible knowledge work.

Key Risks